Drug intelligence / Profile preview

TRS-021

Development stage: Preclinical
Lead developer: Zhejiang Teruisi Pharmaceutical

Overview

TRS-021 is a biological product under development by Zhejiang Teruisi Pharmaceutical. It is being investigated for the treatment of neoplasms (cancers). As of March 2025, its highest global R&D status is preclinical, and it has not yet entered clinical trials in humans. The specific mechanism of action, molecular target(s), and modality have not been publicly disclosed. The drug's development appears to be focused on oncology indications[1].

Beyond the preview

Go deeper on TRS-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRS-021.

Explore the full profile